Cyclacel
About Cyclacel Pharmaceuticals

Scientific Advisory Board

Professor Kenneth Harrap, CBE, Ph.D., DSc, F.R.S.C.

Former Director Drug Development Section of the Institute of Cancer Research, Sutton, Surrey and London. Internationally recognized leader in developmental cancer therapeutics. Until September 1997, he was Director of the CRC Centre for Cancer Therapeutics, a multidisciplinary unit responsible for the discovery and development of new anticancer drugs, at the institute of Cancer Research.

With major interests in antimetabolites and platinum-based drugs, he has formed productive collaborations with the pharmaceutical industry that led to the clinical development, registration and marketing of several cancer drugs, including major agents such as Paraplatin® (ref 1) and Tomudex® (ref 2). He received his PhD in chemistry (1961) and his DSc in biochemistry and pharmacology (1997), both from London University, where he is present Professor Emeritus in Biochemical Pharmacology. He has published 400 papers, is on the editorial board of 14 cancer journals and is currently active as a consultant to the pharmaceutical industry.

Professor Harrap has received several honors, including Life and Emeritus Fellowships of the Cancer Research Campaign, the Bruce F Cain Memorial Award (American Cancer Society), the Cain Memorial Award (New Zealand Cancer Society) and the Barnett Rosenberg Award. In 1998, he was appointed CBE for services to cancer research.

Professor Stanley Kaye, M.D. F.R.C.P.

CRC Professor of Medical Oncology, Institute of Cancer Research, The Royal Marsden Hospital. Former Head of Department, CRC Department of Medical Oncology, University of Glasgow and CRC Professor of Medical Oncology, University of Glasgow, since 1981. Professor Kaye is a renowned clinical oncologist who has participated in a large number of early clinical trials of novel anticancer agents.

His particular research interests have been in new drug development, drug resistance, and gynaecological and urological cancer. Professor Kaye's organisational skills have been utilised by various cancer research organisations such as the CRC, EORTC and MRC.

He is currently a non-executive director of West Glasgow Hospitals University NHS Trust. Professor Kaye graduated in London (1972, BSc Biochem. MBBS) and completed training in general medicine and medical oncology in London and Sydney, Australia.

Professor Michel Marty, M.D.

Professor, Medical Oncology, Univ. Paris VII. Director, Oncology Therapeutics Research, Institut Gustave Roussy, Paris. Chairman, International Cancer Collaborative Study Group.

Professor Marty is widely consulted by regulatory authorities on the approvability of cancer drug submissions. He is a member of the Drug Approvals Commission and Chairman of the Antineoplastic Agents Working Group of the National Drug Agency, French Ministry of Health.

He is also an officially designated Expert for the CPMP (Commission for Proprietary Medicinal Products) (ref 3) of the European Union in Brussels and also an Expert for the Transparency Commission (ref 4) of the French Ministry of Health. He received his medical qualification (Doctorat d'Etat en Médecine) and his Master of Sciences in Structural and Metabolic Biochemistry from the University of Paris VII (1975). He is board certified in medical oncology.

Professor Enrico Mihich, M.D.

Director, Grace Cancer Drug Center and Department of Experimental Therapeutics, and Vice President for Sponsored Programs, Roswell Park Cancer Institute, Buffalo, NY, USA.

Renowned for his expertise in cancer research and the development of therapeutics, Dr Mihich is sought after for his advice in a broad variety of subjects relating to cancer research. He is a past President of the American Association of Cancer Research; Chairman of the National Programme Committee of the XIIIth International Cancer Congress; Member of the US National Cancer Advisory Board; Co-chairman of the 1st Joint AACR/JCA Symposium; Chairman of the Pezcoller Symposia Committee; and Chairman or member of multiple international committees.

He was also Assistant Professor in the Department of Pharmacology in the University of Milan. At present Dr Mihich is a member of the Board of Scientific Advisors (BSA) of the National Cancer Institute (USA) and a member of the Council of the International Union Against Cancer (UICC).

Dr Mihich received his M.D. from the University of Milan (1951), a Docent in Pharmacology from the University of Milan (1962), and a Doctor of Medicine, Honoris Causa, from the University of Marseille (1966). Dr Mihich has authored over 400 scientific publications and is a member of the editorial board of twelve peer-reviewed journals.

Professor Karol Sikora, M.D., MA, MB, Ph.D., F.R.C.R., F.R.C.P., F.F.P.M.

Currently Global Clinical Expert-Cancer at AstraZeneca. He is also Visiting Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial College School of Medicine, Hammersmith Hospital, London.

He has been Clinical Director for Cancer Services at Hammersmith since 1990 where he established a major cancer research laboratory funded by the Imperial Cancer Research Fund (ICRF). He became Deputy Director (Clinical Research) of the ICRF and is Special Adviser to HCA Healthcare (private hospital group).

From 1997 to 1999 he was Chief of WHO's Cancer Programme in Lyon and from 1999-2001 Vice President, Global Clinical Research (Oncology) at Pharmacia. He did his clinical training in the UK and was a registrar in oncology at St Bartholomew's Hospital, London.

He obtained his PhD at the MRC Laboratory for Molecular Biology in Cambridge working with Sydney Brenner and spent a year as a clinical fellow at Stanford University, California. He has published over 300 papers and written or edited 17 books.

He is on the editorial board of several journals and is the founding editor of Gene Therapy and Cancer Strategy. He is a former member of the UK Health Department's Expert Advisory Group on Cancer (the Calman-Hine Committee), the Committee on Safety of Medicines and remains an adviser to the WHO Cancer Programme.

Research & Development